Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CAPR
STRONG SELLCapricor Therapeutics, Inc. · Healthcare · United States · $1.1B · Avg Vol: $33M/d
COMPANY DESCRIPTION
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative biological therapeutics for serious diseases, primarily Duchenne muscular dystrophy. Its competitive edge comes from a proprietary cell therapy platform and focus on unmet medical needs in rare diseases, potentially securing significant market share. Capricor is a niche biopharmaceutical company leveraging regenerative medicine approaches, advancing late-stage clinical trials for rare genetic disorders.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.2M | 2.6M | 25.2M | 22.3M | 0 | 349.7% | — | 118.1M | 122.3M | 76.4% |
| EPS | — | -0.51 | -0.83 | -1.15 | -2.26 | — | -2.33 | — | — | — |
| Shares | — | 57.9M | 31.1M | 45.6M | 57.4M | -0.9% | 57.9M | — | — | — |
| Debt | — | 2.6M | 2.2M | 1.5M | 14.5M | 78.3% | 14.8M | — | — | — |
| Equity | — | 11.8M | 22.6M | 145.5M | 305.8M | 196.0% | — | — | — | — |
| Op CF | — | 4.9M | -25.6M | -40.0M | -69.8M | — | -92.6M | — | — | — |
| Inv CF | — | -35.1M | 5.1M | -116.2M | 97.5M | — | — | — | — | — |
| Fin CF | — | 4.9M | 25.6M | 152.8M | 248.9M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CAPR are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CAPR | Capricor Therapeutics, Inc.(you) | $1.1B | 18 | STRONG SELL |
| SVRA | Savara Inc. | $1.1B | 19 | STRONG SELL |
| ORIC | ORIC Pharmaceuticals, Inc. | $1.3B | 21 | SELL |
| PHAT | Phathom Pharmaceuticals, Inc. | $912M | 19 | STRONG SELL |
| VOR | Vor Biopharma Inc. | $1.0B | 14 | STRONG SELL |
| ARDX | Ardelyx, Inc. | $1.2B | 22 | SELL |
| KURA | Kura Oncology, Inc. | $922M | 20 | STRONG SELL |
| ABSI | Absci Corporation | $1.3B | 22 | SELL |
| ANNX | Annexon, Inc. | $855M | 16 | STRONG SELL |
| TSHA | Taysha Gene Therapies, Inc. | $1.6B | 18 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.7%